Comments on Lu Kang Pharmaceutical (600789): the future performance of Tylosin Industry pattern mutation Company is expected.
Comments on Lu Kang Pharmaceutical (600789): rapid growth in performance. Supply of veterinary drugs in short supply drives up prices.
Dynamic follow-up report of Lu Kang Medicine (600789): the quantity and price of veterinary antibiotics rose in both demand-side and supply-side resonance
Lu Kang Pharmaceutical (600789) dynamic follow-up report: environmental protection is stricter and competitors stop production companies benefit significantly
[Qilu Securities] Lu Anti-Medicine: wait for the policy to slow down
[Qilu Securities] Lu Anti-Medicine: antibiotic leader needs urgent transformation
[Qilu Securities] Lu Kang Medicine: the 2010 performance is lower than expected, and it is expected to be a surprise in the first quarter.
[Huachuang Securities] Lu Anti-Medicine: the performance has increased greatly and will benefit from the promotion of the essential drug system in the future.
[Qilu Securities] Lu Anti-Medicine: 7-ACA prices rebounded, Veterinary Drug sales reached a record growth
[Huachuang Securities] Lu Anti-Medicine: pay equal attention to raw materials and preparations, and benefit from the adjustment of product structure.
【齐鲁证券】鲁抗医药:抗生素迎来旺季,7-ACA 扩产提前
【齐鲁证券】鲁抗医药:调整转型中不断实现跨越的抗生素龙头
【华创证券】鲁抗医药:受益基层医疗需求释放,业绩实现爆发式增长
【安信证券】鲁抗医药:受益抗生素行业强劲增长
【中信证券】鲁抗医药:调整结构,享受景气
【齐鲁证券】鲁抗医药:内部整合完成,二次起跑整装待发
【天相投资】鲁抗医药:毛利率整体下滑,四季度或将改善
No Data